We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-1.9%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$647M
AUM Growth
-$194M
Cap. Flow
+$33.7M
Cap. Flow %
5.2%
Top 10 Hldgs %
63.34%
Holding
208
New
51
Increased
38
Reduced
42
Closed
71

Sector Composition

Rank Sector Weight
1 Miscellaneous 73.46%
2 Healthcare 26.22%
3 Consumer Staples 0.17%
4 Financials 0.05%
5 Industrials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TRAW icon
126
Traws Pharma
TRAW
$8.13M
$26K ﹤0.01%
11
-60
-85% -$174K
SCON
127
DELISTED
Superconductor Technologies Inc.
SCON
$21K ﹤0.01%
227
-7,132
-97% -$680K
ROSG
128
DELISTED
Rosetta Genomics Ltd.
ROSG
$19K ﹤0.01%
941,693
+7,085
+0.8% +$2.86K
CVM icon
129
CEL-SCI Corp
CVM
$26M
$15K ﹤0.01%
+553
New +$40.8K
ONTXW
130
DELISTED
Onconova Therapeutics, Inc. Warrants
ONTXW
$8K ﹤0.01%
654,019
NSPRW
131
DELISTED
InspireMD, Inc. Warrants
NSPRW
$8K ﹤0.01%
837,977
-73,396
-8% -$925
BNTCW
132
DELISTED
Benitec Biopharma Limited
BNTCW
$8K ﹤0.01%
+75,904
New +$23K
HMNY
133
PUT
DELISTED
HELIOS & MATHESON INFORMATION TECHNOLOGY INC
HMNY
$8K ﹤0.01%
246
-1,808
-88% -$58.8K
CYTXW
134
DELISTED
Cytori Therapeutics Inc Warrant
CYTXW
$3K ﹤0.01%
+300,413
New +$5.17K
IMUC.WS
135
DELISTED
ImmunoCellular Therapeutics Ltd.
IMUC.WS
$1K ﹤0.01%
+74,443
New +$1.72K
EGLT
136
DELISTED
Egalet Corporation
EGLT
$1K ﹤0.01%
+2,134
New +$1.19K
ABBV icon
137
CALL
AbbVie
ABBV
$465B
-369
Closed -$3.49M
ABEO icon
138
Abeona Therapeutics
ABEO
$313M
-520
Closed -$187K
AKBA icon
139
Akebia Therapeutics
AKBA
$250M
-102,338
Closed -$975K
ALKS icon
140
CALL
Alkermes
ALKS
$7.72B
-676
Closed -$3.92M
ALKS icon
141
PUT
Alkermes
ALKS
$7.72B
-157
Closed -$910K
ALNY icon
142
Alnylam Pharmaceuticals
ALNY
$31.9B
-11,500
Closed -$1.37M
ALNY icon
143
PUT
Alnylam Pharmaceuticals
ALNY
$31.9B
-250
Closed -$2.98M
AMRN
144
Amarin Corp
AMRN
$294M
-1,015
Closed -$62.9K
AQB icon
145
AquaBounty Technologies
AQB
$5.66M
-6
Closed
ARMP icon
146
Armata Pharmaceuticals
ARMP
$164M
-59,426
Closed -$907K
ATNM icon
147
Actinium Pharmaceuticals
ATNM
$39.3M
-66,590
Closed -$729K
AXSM icon
148
Axsome Therapeutics
AXSM
$10.7B
-81,159
Closed -$199K
BMY icon
149
Bristol-Myers Squibb
BMY
$130B
-23,312
Closed -$1.47M
BMY icon
150
PUT
Bristol-Myers Squibb
BMY
$130B
-281
Closed -$1.78M

Similar funds

Sabby Management's Q2 2018 Portfolio in Review

As of Q2 2018, Sabby Management held 208 positions worth $647M, down 23% from $841M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Sabby Management deployed $33.7M of net new capital in Q2 2018, opening 51 new positions and adding to 38 existing holdings. Its largest new stake was Novo Nordisk: 858,710 shares worth $19.8M.

By sector, the portfolio is most concentrated in Miscellaneous at 73% of assets, down from 83% a quarter earlier, followed by Healthcare and Consumer Staples.

On the sell side, the largest reduction was Biogen, an estimated $8.66M trimmed.

  • Sabby Management's largest Q2 2018 buy was Novo Nordisk: 858,710 shares worth $19.8M.
  • Sabby Management added most to Nektar Therapeutics in Q2 2018, an estimated $14.1M increase.
  • Sabby Management's biggest Q2 2018 reduction was Biogen, cutting an estimated $8.66M.
  • Sabby Management fully exited State Street SPDR S&P 500 ETF Trust in Q2 2018, selling an estimated $12M.
  • Sabby Management's ten largest holdings make up 63% of its $647M portfolio in Q2 2018.
  • Sabby Management opened 51 new positions and closed 71 in Q2 2018.
  • Sabby Management's portfolio value fell 23% quarter-over-quarter to $647M.

Based on Sabby Management's 13F filing for Q2 2018, filed 14 Aug 2018.